Company intelligence / Profile preview

Paranta Biosciences

Melbourne, Victoria, Australia

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Paranta Biosciences demonstrated promising preclinical efficacy and safety data for PB01, a recombinant human follistatin therapy. The company initiated a Phase I clinical trial in September 2015 for inhaled PB01 in healthy volunteers, with stages evaluating safety, tolerability, and pharmacokinetics. Preclinical studies showed excellent anti-inflammatory and anti-fibrotic properties with an exceptionally benign toxicological profile.

Therapeutic areas: OncologyPulmonology
Modalities: Recombinant protein
Industry: Biotech

Drug pipeline

1 asset

recombinant human follistatin

Preclinical

Partnerships

Hudson Institute of Medical Research (exclusive commercialization rights for cancer program)

Beyond the preview

Go deeper on Paranta Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paranta Biosciences.

Explore the full profile